To further substantiate the role of the METTL3/FOXO3 axis in liver cancer in vivo, we performed a syngeneic xenograft mouse model by establishing a subcutaneous implantation in C57BL/6 mice with Hepa1‐6 engineered with METTL3 knockdown or FOXO3 overexpression (Appendix Fig S5H) and started drug administration as previously. This evidence concerns the gene FOXO3 and liver cancer.